Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast Cancer
Sand, A.; Duffin, A. T.; Riddell, G. T.; Piacsek, M.; Last, B.; Sun, C.; Richard, R. A.; Tjoe, J. A.; Yin, J.
Show abstract
Despite the great improvement of patient outcomes by trastuzumab, a monoclonal antibody targeted on HER2-positive breast cancer, approximately 23% of patients with early-stage disease treated with adjuvant trastuzumab either fail to respond or experience recurrence within 10 years, highlighting the importance of identifying which HER2-positive patients would benefit from trastuzumab upfront. Efforts to identify biomarkers predictive of response to trastuzumab in initial breast tumor core biopsies have been complicated by the clinical and biological heterogeneity of HER2-positive tumors. Therefore, we identified a trastuzumab-resistant (TrR) signature that accurately predicts response to trastuzumab quantitively and qualitatively in vitro and in vivo, via repurposing transcriptome profiles in an engineered cell line model. We additionally demonstrated that our TrR signature was associated with tumor progression and capable of stratifying patient prognosis. Our study further illustrated the possible mechanism of this resistance as being less inherited cytotoxic T cell infiltration and failure to secrete Interferon-{gamma} upon trastuzumab treatment in TrR tumors. These findings highlight the potential clinical application of TrR signature in treatment management and identifying possible immunotherapy interventions.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- HIF-1 regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer 93%
- Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation 93%
- Reprogramming breast cancer cells to breast cancer stem cell-like by the POU1F1 transcription factor 92%
Similar papers in this journal
- Wnt signaling promotes inflammation and EMT-associated gene expression in mesenchymal TNBC 93%
- Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival 93%
- Proteogenomic Characterization of Triple-Negative Apocrine Carcinoma Reveals Molecular Features of Progression and Chemotherapy Response 92%
Similar papers in this journal
- BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer 92%
- Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer 92%
- Single-cell profiling of tumor-reactive CD4+ T-cells reveals unexpected transcriptomic diversity 92%
Similar papers in this journal
- DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy 92%
- NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer 92%
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study 92%
Similar papers in this journal
- The E3 ligase HECTD4 regulates COX-2 dependent tumor progression and metastasis 91%
- Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade 90%
- Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.